Ozempic semaglutide dose: what each strength is actually for

What doses does Ozempic actually come in, and how are they used?

Ozempic is a once-weekly subcutaneous injection manufactured by Novo Nordisk. In the UK it is available in three pre-filled pens: a 0.25 mg/0.5 mg pen, a 1 mg pen, and a 2 mg pen, giving a total of four possible dose strengths. Treatment starts at 0.25 mg for four weeks. That opening dose is purely a settling-in period while the body adjusts; it has no meaningful blood-sugar effect on its own. The prescriber then steps the dose upward, typically every four weeks, through 0.5 mg and on to 1 mg, which is where many people with type 2 diabetes stay. The 2 mg strength is available for those who need further glycaemic control at that maintenance stage.

Every step in that schedule is a clinical decision. The pace of escalation, the ceiling dose, and whether to continue all depend on how well blood sugar is responding and how tolerable the side effects are. Gastrointestinal effects (nausea in particular) are most noticeable after each increase and usually settle within a week or two. For a detailed look at how dose escalation is managed in the semaglutide class, the NHS's patient information for semaglutide sets out the process clearly.

The 1 mg dose tends to be the one most commonly discussed online, partly because it was the highest strength for several years before the 2 mg pen arrived. That history sometimes leads people to treat 1 mg as a standard endpoint, in practice, it is simply one step in an individually tailored schedule.

How does the Ozempic semaglutide dosage compare with Wegovy's?

The most common question our prescribers field about semaglutide ozempic dose is simple: if both Ozempic and Wegovy contain the same molecule, why do the doses look different? The answer comes down to what each medicine is optimised to do.

Wegovy's schedule runs from 0.25 mg up through 0.5 mg, 1.0 mg and 1.7 mg, reaching 2.4 mg as the standard maintenance dose for weight management. In January 2026 the MHRA approved a further step to 7.2 mg, delivered in a dedicated single-dose pen; that approval specifically covers adults with a BMI of 30 or above. Ozempic tops out at 2 mg, and even that level is calibrated against HbA1c reduction rather than weight-loss targets. The two products share a molecule but not a therapeutic purpose, and that distinction matters under UK licensing law.

Because Wegovy is titrated higher and against different endpoints, switching or converting between the two is not straightforward. The Ozempic-to-Wegovy dose conversion page covers the considerations in more detail, but in every case those decisions sit with a prescriber, not with a dose chart. NICE's appraisal of semaglutide for weight management (TA875) is clear that the weight-management indication and the diabetes indication are assessed entirely separately.

If you are already on Wegovy and want to understand what each step in that schedule involves, the Wegovy dose guide walks through each strength and its purpose.

What's the position on using an Ozempic semaglutide dose for weight loss in the UK?

The MHRA is explicit: GLP-1 receptor agonists are not licensed or assessed for rapid or cosmetic weight loss. Ozempic specifically is authorised for type 2 diabetes. Using it outside that indication (or obtaining it without a prescription from a clinician who has assessed your full medical history) carries real risks, quite apart from legality.

Counterfeit GLP-1 pens have entered the UK supply chain in significant quantities. The MHRA has warned publicly that fake pens have been found to contain insulin and other unlabelled substances. If a seller is offering semaglutide without a clinical consultation, that is a red flag regardless of what label the pen carries.

For weight management specifically, two semaglutide products are licensed in the UK: Wegovy (the weekly injection) and, as of June 2026, Wegovy tablets, the first oral GLP-1 medicine approved for weight loss in Europe. Both require a prescription following proper clinical assessment. The semaglutide dose overview explains how the weight-loss and diabetes schedules differ across the full product range. For context on what private treatment typically costs, the Wegovy pricing page lays out what a legitimate private prescription involves.

If Ozempic isn't right for weight loss, what licensed options exist?

Two medicines are currently licensed in the UK specifically for weight management and are prescribed by nume through private consultation: Wegovy (semaglutide injection, up to 7.2 mg) and Mounjaro (tirzepatide, a dual GIP and GLP-1 receptor agonist, up to 15 mg). Mounjaro is the only dual-agonist weight-loss medicine licensed in the UK, and in the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4 mg over 72 weeks.

Both medicines are prescription-only. Eligibility depends on BMI (typically 30 or above, or 27 with a weight-related health condition) alongside a full clinical assessment. There is no waiting list through a private regulated pharmacy; a GPhC-registered prescriber reads your consultation the same day. Once approved, your treatment is dispatched and arrives via DPD the next working day in plain, unbranded packaging, nothing on the outside identifies what's inside.

A full look at both weight-loss treatments is on the weight-loss treatments overview. If you have questions before starting, the FAQs page covers the most common ones, or you can contact the team directly. The semaglutide dose escalation guide is worth reading if the titration schedule is what you wanted to understand before deciding.